IMMUNITYBIO, INC. Proceeds from Issuance or Sale of Equity
IMMUNITYBIO, INC. (IBRX) reported Proceeds from Issuance or Sale of Equity of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2018-03-12
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for the quarter ending 2015-12-31 was $263.00K, a 99.54% decline year-over-year.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for the quarter ending 2015-09-30 was $245.21M, a 310296.20% increase year-over-year.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for the quarter ending 2014-12-31 was $57.34M.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for the quarter ending 2014-09-30 was $79.00K.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for fiscal 2017 was $0.00.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for fiscal 2015 was $316.45M, a 401.37% increase from fiscal 2014.
- IMMUNITYBIO, INC. proceeds from issuance or sale of equity for fiscal 2014 was $63.12M, a 9236.98% increase from fiscal 2013.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2015-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $245.48M derived: sum of 2 quarters · filed 2018-03-12 | $316.45M 10-K · filed 2018-03-12 | |
| 2015-09-30 | $245.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $316.19M 10-Q · filed 2015-11-12 | ||
| 2015-06-30 | $70.98M 10-Q · filed 2015-09-10 | |||
| 2014-12-31 | $57.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $57.42M derived: sum of 2 quarters · filed 2017-03-15 | $63.12M 10-K · filed 2017-03-15 | |
| 2014-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $5.78M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $5.70M 10-Q · filed 2015-09-10 | |||
| 2013-12-31 | $676.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |